FDA Review posts the Federal Register notices for the week ending 10/22/2021.
FDA Review posts product approval summaries for the week ending 10/22/2021.
Federal Register notice: FDA withdraws the approval of 216 ANDAs from multiple holders because they repeatedly failed to submit required annual report...
Federal Register notice: FDA makes available a draft guidance entitled Data Standards for Drug and Biological Product Submissions Containing Real-Worl...
Federal Register notice: FDA determines that 20 listed drug products were not withdrawn from sale due to safety or effectiveness issues.
FDA issues a clinical hold against Tryp Therapeutics and a Phase 2a study evaluating its psilocybin for eating disorders.
Agenus withdraws a BLA for balstilimab after FDA urged it to do so following Mercks recent full approval for pembrolizumab for treating cervical cance...